Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$26.01 USD
-0.90 (-3.34%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $25.99 -0.02 (-0.08%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth A Momentum F VGM
Brokerage Reports
Verona Pharma PLC American Depositary Share [VRNA]
Reports for Purchase
Showing records 121 - 140 ( 195 total )
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life SciencesThis report contains brief updates on the following: BMRN, VYGR, AQST, AXLA, ICPT, IMUX, VRNA, BPMC, MGNX. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Financing Clears Key Overhang; All Set to Start Ensifentrine Ph 3 in H2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine/COPD ENHANCES to Phase 3; KOLs Enthusiastic
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
FDA?s EOP2 Response Supports Ph3 ENHANCE Program Initiation
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q1; Ensifentrine/COPD: FDA?s EOP2 Response Anticipated in Q2; Ph3 Start in Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
2020 Updated Outlook; Verona Can Manage Nebulized Ph 3 but Financing Required
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Positive Data for Ph2 pMDI Single Dose; Multiple Dose Postponed Due to COVID-19
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L